Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Finished Goods (2019 - 2025)

CorMedix's Finished Goods history spans 5 years, with the latest figure at $14.4 million for Q4 2025.

  • For Q4 2025, Finished Goods rose 385.98% year-over-year to $14.4 million; the TTM value through Dec 2025 reached $14.4 million, up 385.98%, while the annual FY2025 figure was $14.4 million, 385.98% up from the prior year.
  • Finished Goods for Q4 2025 was $14.4 million at CorMedix, up from $12.8 million in the prior quarter.
  • Across five years, Finished Goods topped out at $14.4 million in Q4 2025 and bottomed at $245668.0 in Q2 2021.
  • The 3-year median for Finished Goods is $1.6 million (2024), against an average of $3.9 million.
  • The largest annual shift saw Finished Goods plummeted 39.79% in 2021 before it skyrocketed 1233.22% in 2025.
  • A 3-year view of Finished Goods shows it stood at $245668.0 in 2021, then soared by 1105.29% to $3.0 million in 2024, then surged by 385.98% to $14.4 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Finished Goods are $14.4 million (Q4 2025), $12.8 million (Q3 2025), and $3.3 million (Q2 2025).